ArticleOrphanet journal of rare diseases2025
"My dream is to not have to be on a diet": a qualitative study on burdens of classical homocystinuria (HCU) from the patient perspective.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Outcomes of the national premarital genetic screening program for cystic fibrosis, homocystinuria, and spinal muscular atrophy in Qatar.Human genomics · 2026Article
- Homocystinuria: Advances in metabolic and molecular therapies targeting homocysteine pathways (Review).Molecular medicine reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPatients with classical homocystinuria (HCU) are unable to metabolize homocysteine and rely on dietary treatment to reduce their risk of complications (e.g., thromboembolism, cognitive impairment). Little is known about how patients are affected by their HCU disease experience.
methodsOne-on-one, semi-structured interviews were conducted in adult and pediatric patients (aged ≥ 12 years) with HCU and in primary caregivers on behalf of pediatric patients aged 5-17 years. Interviews elicited patients' experiences with signs, symptoms, and impacts of HCU. Participants listed their most-bothersome signs/symptoms and impacts and were asked about what changes in HCU treatment would improve their everyday lives.
resultsEleven adult patients, two pediatric patients, and seven caregivers (of non-participating patients) participated. Many were most bothered by cognition-related symptoms (n = 7, 35%) and fatigue (n = 6, 30%). Nearly all participants (n = 19, 95%) struggled with the "very restricted [low-protein] diet" and the "disgusting" and inconvenient medical formula. The dietary restrictions and requirements often led to challenges fitting in socially. Psychological impacts of HCU (e.g., anxiety, depression) were highly prevalent (n = 16, 80%) and bothersome (n = 9, 45%). Many patients experienced financial burdens related to their dietary treatment (n = 14, 70%). Most participants wanted a treatment involving less formula or a more relaxed diet (n = 12, 60%) and felt that these changes would meaningfully improve their everyday lives.
conclusionsMost patients were burdened by adhering to dietary treatment and by symptoms that worsened when they did not adhere to treatment. These findings can be used to inform treatment goals and care to improve patients' everyday lives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.